Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024 - Seite 2

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240401305012/en/

The Acorda Therapeutics Stock at the time of publication of the news with a fall of -9,35 % to 0,502USD on Nasdaq stock exchange (03. Juni 2023, 02:00 Uhr).